Cytokinetics (CYTK) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $63.31 --0%
EPS Growth %: +43.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ZVOI, SYRS, ATRA, More
EPS Growth %: +43.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ZVOI, SYRS, ATRA, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.50), $0.06 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $17.76 million versus the consensus estimate of $7.12 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sensient Technologies (SXT) Tops Q3 EPS by 4c, Misses on Revenue; Offers FY26 EPS Guidance
- OneMain Financial (OMF) Misses Q3 EPS by 8c
- Adamas Trust, Inc. (ADAM) PT Lowered to $7.50 at B.Riley
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
